Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von John Politis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Monash Lung Sleep Allergy and Immunology, Monash University and Medical Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Asthma, Registries, Adrenal Cortex Hormones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
People with severe asthma remain at risk of toxicity from maintenance oral corticosteroid (OCS) use and/or frequent OCS burst therapy. Cumulative exposures above 500–1000 mg prednisolone are associated with adverse effects, and recently OCS stewardship principles were promulgated to guide OCS prescription.
Aims
To examine real‐world registry data to quantify OCS burden, ascertain trends over time in prescription and assess whether opportunities to implement steroid‐sparing strategies were utilised.
Methods
Participants were enrolled in the Australasian Severe Asthma Registry for the period 2013–2021. Assessments were taken at enrolment and then annual follow‐up, which included asthma control and OCS use. Descriptive analyses were performed, and subgroups were compared at baseline and over time.
Results
Nine hundred and twenty‐four participants were evaluated and 215/924 (23%) were taking maintenance OCS at baseline, with 44% and 32% of participants having exposure to ≥500 or 1000 mg of OCS respectively in the prior year. Twelve months later, an additional 10% and 9% of participants reached cumulative doses of 500 or 1000 mg. People exceeding thresholds had ongoing poor asthma control. At baseline, 240/924 (26%) people were treated with asthma biological therapy. An additional 83 (12%) participants were identified as potentially benefiting from this steroid‐sparing medication. Of these patients, only 23% commenced a biologic agent in the next 12 months.
Conclusions
A large national asthma registry identifies exposure to toxic cumulative doses of OCS in more than a third of participants, with further subsequent cumulative dose escalation over 2 years. Steroid‐sparing strategies were often not employed, highlighting the need for implementation of OCS stewardship initiatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Lung Sleep Allergy and Immunology, Monash University and Medical Centre, Melbourne, Victoria, Australia.
- Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
- Thoracic Society of Australia and New Zealand, Chatswood, New South Wales, Australia.
- Hudson Institute, Monash University, Melbourne, Victoria, Australia.
- College of Health Medicine and Wellbeing, The University of Newcastle, New Lambton Heights, New South Wales, Australia.
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
ORCID-Profile: John Politis
Zitieren
APA
Politis, J., Chung, L. P., Igwe, E., Bardin, P., & Gibson, P. G. (2024). Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry. Internal Medicine Journal. https://doi.org/10.1111/imj.16392
Vancouver
Politis J, Chung LP, Igwe E, Bardin P, Gibson PG. Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry. Internal Medicine Journal. 2024. doi:10.1111/imj.16392
BibTeX
@article{Politis2024,
author = {Politis, John and Chung, Li Ping and Igwe, Ezinne and Bardin, Philip and Gibson, Peter G},
title = {Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16392}
}
EUVIMED